Microparticles and endothelial function—A tour de force

Ferraris, Victor A.

doi:10.1016/j.jtcvs.2015.06.011

Cited by 3 publications

(4 citation statements)

References 13 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence suggests that the role of EMPs is more complex than initially perceived and that it is unclear whether EMPs-mediated alterations are part of physiological vascular homeostasis or if they contribute to pathological conditions ( 10 , 11 , 12 ). In our study, there was no evidence of endothelial impairment (Endo-PAT) in response to treatment with empagliflozin or metformin.…”

Section: Discussionmentioning

confidence: 99%

“…Endothelial microparticles (EMPs) are extracellular vesicles formed by membrane blebbing of activated or apoptotic endothelial cells and packaging of proteins, some of which are established markers of endothelial injury such as PECAM-1, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin, endoglin and vascular endothelial growth factor (VEGF) ( 9 , 10 , 11 , 12 , 13 ). Techniques to measure EMPs rely on the preparation of platelet-free plasma and subsequent identification of cell-surface proteins (e.g.…”

Section: Introductionmentioning

confidence: 99%

“…EMPs synthesis is stimulated by inflammatory cytokines, reactive oxygen species (ROS), lipopolysaccharides, thrombin and low shear stress. In turn, by facilitating the interactions of endothelial cells with immune cells, EMPs are involved in endothelial cell modifications, inflammation, coagulation and angiogenesis ( 9 , 10 , 11 , 12 , 13 ). Elevated EMP levels have been associated with cardiovascular and autoimmune diseases, cancer, endocrine and metabolic disorders and, therefore, they are often used as surrogate markers of endothelial dysfunction in these conditions ( 14 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome

Javed

Papageorgiou

Madden

et al. 2020

Endocrine Connections

View full text Add to dashboard Cite

Context Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. Objective To characterise and compare the effects of empagliflozin vs metformin on the circulating levels of EMPs in overweight/obese women with PCOS. Methods This was a randomised, comparative, 12-week single-centre trial conducted at the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This analysis includes data from 39 overweight/obese women with PCOS who completed the study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment and analysed for specific surface proteins (ICAM-1, VCAM-1, PECAM-1, E-selectin and endoglin) expressed by circulating EMPs using flow cytometry. Results In the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, whereas all other EMPs remained unchanged. When data were expressed as percentage change from baseline in each group, no significant differences were seen between groups for any biomarker (P-values from 0.22 to 0.80). Conclusions Short-term administration of empagliflozin and metformin in overweight/obese women with PCOS appear to increase EMPs expressed by endothelial cells during their activation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome

Javed

Papageorgiou

Madden

et al. 2020

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…Endothelial microparticles (EMPs) are extracellular vesicles produced from membrane blebbing of protein packaging and activated or apoptotic endothelial cells after the interaction of several factors, such as low shear stress, reactive oxygen species (ROS), inflammatory cytokines, lipopolysaccharides, and thrombin [ 120 , 121 ]. They are commonly used as surrogate markers of endothelial dysfunction in several conditions.…”

Section: Pcosmentioning

confidence: 99%

Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state

Papaetis¹

2021

Arch Med Sci Atheroscler Dis

View full text Add to dashboard Cite

Empagliflozin is a SGLT2 inhibitor that has shown remarkable cardiovascular and renal activities in patients with type 2 diabetes (T2D). Preclinical and clinical studies of empagliflozin in T2D population have demonstrated significant improvements in body weight, waist circumference, insulin sensitivity, and blood pressure -effects beyond its antihyperglycaemic control. Moreover, several studies suggested that this drug possesses significant anti-inflammatory and antioxidative stress properties. This paper explores extensively the main preclinical and clinical evidence of empagliflozin administration in insulin resistance-related disorders beyond a diabetic state. It also discusses its future perspectives, as a therapeutic approach, in this high cardiovascular-risk population.

show abstract

Surgery and Hemostasis

Lawson¹,

Kitchens²

2019

Consultative Hemostasis and Thrombosis

View full text Add to dashboard Cite

Microparticles and endothelial function—A tour de force

Cited by 3 publications

References 13 publications

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome

Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state

Surgery and Hemostasis

Contact Info

Product

Resources

About